Business Of Biotech

Approvals & Mergers: Inside Enzyvant with Bill Symonds, Pharm.D.

Apr 3, 2023
Ask episode
Chapters
Transcript
Episode notes
1
Introduction
00:00 • 2min
2
Enzavant's Approval of a One-Time Regenerative Tissue-Based Therapy for Pediatric Congenital Athena
01:58 • 2min
3
The Importance of Sticking With Your Career Path
04:24 • 2min
4
The Importance of Farm D in Leadership
06:23 • 3min
5
How to Be an Entrepreneur in a Company
09:05 • 5min
6
Roy Vance's Progression in Arbatus
14:08 • 2min
7
Royvent's Chief Development Officer
16:21 • 4min
8
The Power of Progression
19:55 • 2min
9
The Why and How of the Alt Event Ends Event Merger
21:56 • 4min
10
The Importance of Complementary Assets in Biopharma
26:03 • 2min
11
The Struggles of Altavant and Rethomica
28:23 • 2min
12
The Decision to Build a Regenerative Manufacturing Facility
30:43 • 2min
13
The Ease of Procurement and Supply Chain Issues
33:03 • 2min
14
Enzavant Connect: A Patient Outreach Program for Regenerative Medicine Therapies
34:37 • 4min
15
The Importance of Ends-Event Connect for Patients
38:13 • 2min
16
Ends-Event Connect for Pulmonary Artery Hypertension
39:55 • 2min
17
Radetra Stat Ethyl: A Drug for Pulmonary Artery Hypertension
41:58 • 4min
18
The Potential for a Commercialized Drug for Pulmonary Artery Hypertension
45:28 • 2min
19
Rhythymics: A Small Molecule Manufacturing Company
47:41 • 2min
20
Rhythymic's Plans for the Future
49:31 • 2min
21
How to Interview for a Career in Pharmacology
51:12 • 3min
22
Dr. Simmons: The Value of Humility in the Biotech Industry
54:24 • 2min